Ground-glass opacity adenocarcinoma of the lung
Conditions
Interventions
Sponsors
Meishan City Peoples Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or older, regardless of gender, with a chest CT-confirmed GGN and scheduled for lobectomy or segmentectomy. 2. Postoperative pathology confirmed the nature of the nodule (benign or malignant) and the pathological subtype of adenocarcinoma (Adenocarcinoma in Situ, Minimally Invasive Adenocarcinoma, or Invasive Adenocarcinoma). 3. No prior antitumor therapy (e.g., chemotherapy, targeted therapy) was received before surgery, and no sex hormone medications were used within 1 month preoperatively. 4. Serum samples were collected preoperatively after fasting for estradiol measurement, and the resected nodule specimens were obtained postoperatively. 5. With complete clinical data, including age, gender, smoking history, CT characteristics of the nodule, and surgical approach.
Exclusion criteria
Exclusion criteria: 1. Exclusion of patients with concurrent malignancies of other systems (e.g., breast cancer, ovarian cancer). 2. Presence of endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome) or severe hepatic/renal dysfunction. 3. Pregnant and/or lactating women. 4. Inadequate specimen fixation (e.g., failure to fix within 30 minutes post-resection) or suboptimal immunohistochemical staining quality. 5. Incomplete clinical data (e.g., unrecorded smoking history or incomplete CT parameters). 6. Malignant nodules with histology other than adenocarcinoma (e.g., squamous cell carcinoma, small cell carcinoma) or benign nodules of unclear etiology (e.g., inability to differentiate between an inflammatory nodule and a fibrotic focus).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| estrogen receptor;Serum estrogen levels; | — |
Countries
China
Contacts
Public ContactYongkang Yu
Meishan City Peoples Hospital
Outcome results
None listed